Wedbush raised the firm’s price target on Dianthus (DNTH) to $42 from $34 and keeps an Outperform rating on the shares. The firm added claseprubart in the chronic inflammatory demyelinating polyneuropathy setting into the model. Data points from Sanofi (SNY) provide a read through for claseprubart’s potential CIDP utility, the analyst tells investors in a research note. Wedbush says that given claseprubart’s increased potency and similar trial design versus riliprubart, it likes the chances for claseprubart success in CIDP.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNTH:
- Dianthus Therapeutics: Promising Developments and Market Potential Drive Buy Rating
- Promising Clinical Developments and Financial Stability Drive Buy Recommendation for Dianthus Therapeutics
- Dianthus Therapeutics Reports Q2 2025 Financial Results
- Dianthus Therapeutics: Promising Prospects with DNTH103 and Strong Financial Position Support Buy Rating
- Promising Outlook for Dianthus Therapeutics: Buy Rating on Claseprubart’s Potential in gMG